Number 7? Celgene partner BeiGene joins the crowd with stellar PD-1/L1 data from a pivotal test
Get ready for the second wave of PD-1/L1 checkpoint inhibitors.
BeiGene $BGNE announced just ahead of the start of the week in Beijing that their PD-1 tislelizumab — partnered with Celgene $CELG — scored stellar data in a small Phase II trial for classical Hodgkin’s lymphoma among patients who had either failed or couldn’t take autologous stem cell transplantation. This is their first pivotal trial, and it underscores why Celgene inked a $1.4 billion deal to buy into the drug — which may end up as the 7th new checkpoint to hit the global market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.